The potential of UK clinical databases in enhancing paediatric medication research
Non-U.S. Gov't; PedPal Lit; Newborn Medical Records Systems; Adolescent Adverse Drug Reaction Reporting Systems Biomedical Research/methods Child Child; Computerized Pediatrics/methods Pharmaceutical Preparations/administration & dosage Pharmacoepidemiology/methods Prescriptions; Drug/statistics & numerical data Research Support; Factual Family Practice/statistics & numerical data Great Britain Humans Infant Infant; PreschoolDatabases
The research potential of many UK clinical databases is not being realized. A recent report published by the Royal College of Paediatrics & Child Health stated that there is a need to build research capacity and support in the area of paediatric pharmacology, with specific emphasis on the use of clinical databases. This article presents the databases available in the UK for medication research and gives some examples of paediatric studies conducted. The databases discussed include the Prescription Pricing Authority database, the General Practice Research Database, IMS Health databases (Medical Data Index, MIDAS Prescribing Insights, Disease-Analyser-Mediplus) and the Yellow Card Scheme. Other databases such as the Medicines Monitoring Unit (MEMO) and the Scottish Primary Care Computer System also have research potential in paediatric pharmacoepidemiology, but their population sizes are relatively small.
2005
Wong IC; Murray ML
British Journal of Clinical Pharmacology
2005
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.1111/j.1365-2125.2005.02450.x" target="_blank" rel="noreferrer">10.1111/j.1365-2125.2005.02450.x</a>
Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care
PedPal Lit; 11; 2-4; 22; 26; 5-11; Adolescent Anticonvulsants/administration & dosage/adverse effects Child Child; and 12-17-year-old age groups; and 12-17-year-olds; and 33/1000 children chronically prescribed antiepileptic therapy in the 0-1; and six for the 0-1; ciprofloxacin; Computerized Polypharmacy Prescriptions; Drug/statistics & numerical data Primary Health Care/statistics & numerical data Research Support; erythromycin; Newborn Medical Records Systems; Non-U.S. Gov't Scotland%X AIMS: To investigate the extent of acute coprescribing in primary care to children on chronic antiepileptic therapy; Preschool Drug Administration ScheduleDrug Interactions Epilepsy/drug therapy Humans Infant Infant; respectively. Of these acute coprescriptions 72 (1.5%) prescribed to 22 (3.0%) children were identified as a potential source of clinically serious interactions. The age-adjusted prevalence rates for potentially serious coprescribing were 86; respectively. The drugs most commonly coprescribed which could give rise to such interactions were antacids; six; theophylline and (TRUNCATED); with carbamazepine
2005
Novak PH; Ekins-Daukes S; Simpson CR; Milne RM; Helms P; McLay JS
British Journal of Clinical Pharmacology
2005
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.1111/j.1365-2125.2004.02237.x" target="_blank" rel="noreferrer">10.1111/j.1365-2125.2004.02237.x</a>